gerade frisch bei Stockhouse gefunden: (ich hab mal die anderen Sachen rausgelöscht) 1/9/2007 Jan 09, 2007 (M2 PRESSWIRE via COMTEX News Network) -- RealPennies.com ALERTS: reporting on dollar volume movers: Cyberlux Corporation (OTCBB CYBL), One Voice Technologies, Inc. (OTCBB ONEV), Nanosensors, Inc. (OTCBB NNSR), Imaging Diagnostic Systems, Inc. (OTCBB IMDS), Grant Life Sciences, Inc. (OTCBB GLIF), and Drinks Americas Holdings, Ltd. (OTCBB DKAM).
Grant Life Sciences, Inc. (OTCBB GLIF) Monday's market went down 8.04% to $0.103 per share, with a total of 3,634,746 shares traded.
The company announced that it has received a cash infusion of $400,000. The company intends to use this cash to fill outstanding orders for its products and continue validating its in-licensed diagnostic opportunities. "Taking in a relatively small amount of money--$400,000--at this time provides us with a short-term connection to what management hopes will be a much larger opportunity," said Hun-Chi Lin, Ph.D., Grant's President and Chief Scientist. "Indeed, we believe our eagerness to announce this 'small' event should give our investors a sense of confidence about the longer-term prospects for Grant Life Sciences, given the recent announcements which demonstrate that we are executing our new corporate strategy to: (1) acquire new products and technologies via in-licensing activities; (2) out-license products for further development and sales; and (3) drive sales through our established marketing channels. We believe that this funding event underscores management's bullishness about Grant's prospects in this new year." Grant Life Sciences, Inc. engages in the research, development, marketing, and sale of diagnostic kits for detecting low-grade cervical disease in the United States. The company's tests detect the presence of antibodies that are produced when cervical cancer or certain precancerous conditions are present in the body by analyzing a small amount of the patient's blood. It also holds worldwide rights to diagnostic devices for HIV-1, HIV-2, and dengue fever testing; and a proprietary diagnostic reagent, an ingredient used by manufacturers of rapid tests. Grant Life was founded in 1998 and is based in Los Angeles, California. Grant Life Sciences, Inc. is a wholly owned subsidiary of Grant Ventures, Inc.
|